New AI-driven technology for breast cancer screening

Developments with artificial technology are transforming medical diagnosis.

A new offering from the company iCAD is a prime example, helping medics to assess for Digital Breast Tomosynthesis and other signs of breast related cancer.

iCAD has showcased its Breast Health Solutions suite at the Radiological Society of North America Annual Meeting annual meeting, held during December 2019. This included the technology ProFound AI for Digital Breast Tomosynthesis (DBT), which is said to be the first artificial intelligence software for DBT to be approved by the U.S. Food and Drug Administration (FDA). […]

Click here to view original web page at www.digitaljournal.com